SynthesisMedicine2025
Causal validation between 179 lipids and hyperparathyroidism: A bidirectional Mendelian randomization combined meta-analysis with mediation factors.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperparathyroidism, an endocrine disorder linked to hypercalcemia, increases with age, particularly in those over 60. Abnormal lipid metabolism may be closely related to its occurrence and progression. The study used Mendelian randomization (MR) analysis on 179 lipid traits against hyperparathyroidism in the Finngen and UK Biobank (UKB) databases. Meta-analysis of inverse variance weighted results followed, with significance P-values corrected for multiple comparisons. Causal validation was performed between positive lipids and renal failure, and MR analysis examined the link between renal failure and hyperparathyroidism. Reverse causal validation was also conducted between lipids and hyperparathyroidism, positive lipids and renal failure, and renal failure and hyperparathyroidism. The study conducted causal validation between 179 lipid traits and hyperparathyroidism, also exploring intermediary factors. Ultimately, MR analysis was performed on triacylglycerol (52:3) levels with hyperparathyroidism in both Finngen and UKB databases, followed by meta-analysis and multiple corrections. The results showed an odds ratio (OR) of 1.147 (95% confidence interval [CI]: 1.065-1.235, P = .040). The MR results for triacylglycerol (52:3) levels and renal failure indicated an OR of 1.054 (95% CI: 1.004-1.106, P = .032). For the intermediary factor renal failure, MR analysis with hyperparathyroidism in both Finngen and UKB databases followed by meta-analysis showed an OR of 1.336 (95% CI: 1.193-1.495, P = 4.78 × 10-7). Notably, no significant associations were found in the reverse validation of each analysis process. Furthermore, the mediation effect was β12 = 0.0153, and the direct effect was β3 = 0.1207 (0.1183, 0.1230). The mediation effect accounted for 11.25%, while the direct effect accounted for 88.75% of the total effect, Z = 12.5, indicating that the direct effect predominantly influences the overall impact. The research shows that triacylglycerol (52:3) levels can directly increase the risk of hyperparathyroidism. It also raises the risk indirectly by increasing the likelihood of renal failure, an intermediary factor. About one-tenth of the lipid's effect on hyperparathyroidism is mediated through renal failure, while the direct effect constitutes roughly nine-tenths of the total effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.